Efficacy and Safety of SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients with Heterozygous Familial Hypercholesterolemia

Registry ID

EUCTR2012-001096-37

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

sanofi-aventis Recherche & Développement

Start date

2012-07-05

Last update

2026-08-16

Conditions

• Hypercholesterolaemia

Summary

To evaluate the effect of SAR236553 (REGN727) on low-density lipoprotein cholesterol (LDL-C) levels after 24 weeks of treatment in comparison with placebo.

Locations

• , , Netherlands

Related clinical trials

• A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia
• A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
• An Efficacy and Safety Study of Akkermansia Muciniphila AKM Lab-01 in Hypercholesterolaemia
• Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
• Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy
• LATAM LOWERS LDL-C

View on source registry